DrugPatentWatch Database Preview
Patent: 10,066,019
» See Plans and Pricing
Summary for Patent: 10,066,019
| Title: | Optimised heavy chain and light chain signal peptides for the production of recombinant antibody therapeutics |
| Abstract: | Antibodies of interest comprising a heavy chain signal peptide and/or a light chain signal peptide or combination thereof and compositions are described. The method of determining the signal peptide including creating data set of antibodies signal peptides, clustering, selecting and creating recombinant antibodies for enhanced expression and secretion are described. |
| Inventor(s): | Song; Zhiwei (Singapore, SG) |
| Assignee: | Agency for Science, Technology and Research (Singapore, SG) |
| Application Number: | 14/435,094 |
| Patent Claims: | see list of patent claims |
Details for Patent 10,066,019
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Genentech | RITUXAN | rituximab | SOLUTION;INTRAVENOUS | 103705 | 001 | 1997-11-26 | Start Trial | Agency for Science, Technology and Research (Singapore, SG) | 2032-10-12 | RX | search | |
| Genentech | RITUXAN | rituximab | SOLUTION;INTRAVENOUS | 103705 | 002 | 1997-11-26 | Start Trial | Agency for Science, Technology and Research (Singapore, SG) | 2032-10-12 | RX | search | |
| Centocor Inc | REMICADE | infliximab | VIAL | 103772 | 001 | 1998-08-24 | Start Trial | Agency for Science, Technology and Research (Singapore, SG) | 2032-10-12 | RX | Orphan | search |
| Genentech | HERCEPTIN | trastuzumab | VIAL; INTRAVENOUS | 103792 | 001 | 1998-09-25 | Start Trial | Agency for Science, Technology and Research (Singapore, SG) | 2032-10-12 | RX | Orphan | search |
| Abbvie Inc | HUMIRA | adalimumab | SYRINGE | 125057 | 001 | 2002-12-31 | Start Trial | Agency for Science, Technology and Research (Singapore, SG) | 2032-10-12 | RX | search | |
| Abbvie Inc | HUMIRA | adalimumab | VIAL | 125057 | 002 | 2002-12-31 | Start Trial | Agency for Science, Technology and Research (Singapore, SG) | 2032-10-12 | RX | search | |
| Genentech | AVASTIN | bevacizumab | VIAL; INTRAVENOUS | 125085 | 001 | 2004-02-26 | Start Trial | Agency for Science, Technology and Research (Singapore, SG) | 2032-10-12 | RX | Orphan | search |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
International Patent Family for US Patent 10,066,019
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| China | 104854133 | Start Trial |
| European Patent Office | 2906599 | Start Trial |
| Singapore | 11201502816Y | Start Trial |
| United States of America | 2015225482 | Start Trial |
| World Intellectual Property Organization (WIPO) | 2014058389 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
